Omeros Corporation
Clinical trials sponsored by Omeros Corporation, explained in plain language.
-
Drug trial halted after testing for rare kidney conditions
Disease control TerminatedThis study tested an experimental drug called OMS721 (narsoplimab) in adults with four serious kidney diseases. The main goals were to check the drug's safety and see if it could reduce harmful protein in the urine, a key sign of kidney damage. The trial was terminated early and …
Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Experimental drug tested for rare, Life-Threatening blood disorder
Disease control TerminatedThis study tested an experimental drug called OMS721 (narsoplimab) for adults and adolescents with atypical hemolytic uremic syndrome (aHUS), a rare and serious blood disorder that can damage kidneys. The main goal was to see if the drug could safely increase platelet counts and …
Phase: PHASE3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Drug trial aims to halt silent kidney killer
Disease control TerminatedThis study tested whether the drug OMS721 (narsoplimab) could slow the progression of IgA nephropathy, a kidney disease. It involved about 360 adults with confirmed disease and high levels of protein in their urine. The main goal was to see if the drug could significantly reduce …
Phase: PHASE3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC